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Background: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer. Clinicians 
commonly refer to surgical therapy as resection with curative intent. However, PDA cure rates 
after resection remain unknown and the definition of cure remains vague. We investigated how 
patients (the majority undergoing resection), family members, and clinicians understand the 
concept of cure, to better inform discussions with patients regarding PDA prognosis.  
Methods: In a prospective survey, cohorts were asked to indicate the best definition of cure from 
three choices: 5-year survival endpoint (typically used in the literature); a biological endpoint 
without biochemical or radiographic signs of disease (similar to the NCI definition); or a 
practical endpoint where life span approximates similarly aged patients without PDA. Fleiss’ 
kappa statistic was calculated to measure inter-rater agreement.  
Results: Patients, family members and health care professionals (N=200) agreed that 
renormalization of life expectancy was the preferred definition of cure in the context of 
pancreatic cancer. Inter-rater agreement was highest for the patient and family member groups 
(Fleiss’ Kappa 0.27 and 0.40 respectively. P<0.001), while variability was observed between 
health care professionals (Fleiss’ Kappa 0.11, P<0.001). 
Conclusions: In all groups surveyed, the probability for a normal life expectancy is the preferred 
long-term metric in patients with early-staged pancreatic cancer. Renormalization of life 
expectancy appears to be an important therapy goal for PDA patients and it is advisable to 





Pancreatic cancer is currently the third leading cause of cancer death in the United 
States1, and is expected to become second to lung cancer within the next decade. The disease is 
highly lethal with an overall 5-year survival of only 9%1-3. Patients with advanced disease have 
five-year survival rates of just 3%2,3. Approximately 20% of patients with PDA have localized 
and resectable disease at diagnosis and this group has the best long-term outcome. In this 
resected subgroup, five-year survival rates are 15-18%4-6. In fact, patients undergoing resection 
for PDA are the only ones believed to have a realistic chance for cure. 
A cancer cure is the ultimate hope for every patient. Clinicians may occasionally suggest 
a possibility of this desired outcome during preoperative discussions. In some cases, clinicians 
may even suggest that a cure has been achieved, particularly after a long follow-up interval. 
However, to our knowledge, there has never been an attempt to quantify cure rates after PDA 
resection. To date, the five-year survival rate has been the gold standard definition for long-term 
outcome in this cohort. Importantly, a small number of studies with longer follow-up clearly 
indicate that recurrences and cancer-specific mortality occur beyond this 5-year time point6.  
Moreover, while conventional clinical survival endpoints (cancer-specific mortality, disease free 
survival, etc.)7 are useful for research studies and clinical trials to benchmark progress, they may 
have less meaning for patients and their families who are unaccustomed to processing statistical 
information. 
The NCI provides the following statement on cancer cure 8:  
“Cure means that there are no traces of your cancer after treatment and the cancer will never 
come back…If you remain in complete remission for 5 years or more, some doctors may say that 
you are cured. Still, some cancer cells can remain in your body for many years after treatment. 
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These cells may cause the cancer to come back one day. For cancers that return, most do so 
within the first 5 years after treatment. But, there is a chance that cancer will come back later. 
For this reason, doctors cannot say for sure that you are cured. The most they can say is that 
there are no signs of cancer at this time.” 
Not only is a cancer cure impossible to determine clinically, but application of this definition 
assumes that patients desire, above all else, to have their disease eradicated and for it to never 
return. But what if patients die prematurely for other reasons, such as from complications of their 
surgery or chemotherapy? Such an outcome is clearly less desirable than a biologic cure. On the 
other hand, a ‘healthy’ normal life span may be a more appealing endpoint, even if there remains 
radiologic or biochemical evidence of indolent, non-active disease.  
In population-based biostatistics, cure is defined as the normalization of the mortality rate 
in the affected population back to the same level as in the general population9. Several studies 
have looked at this definition in an attempt to estimate cancer cure rates10,11. However, the use of 
this definition is still mainly limited to cross-sectional population based studies with minimal use 
in the clinical setting. Determining the best survival endpoint and definition of cure has 
important implications for surveillance strategies, as well as for discussions between clinicians 
and patients. Thus, we sought to determine a practical definition of cure with objective, 
quantifiable end-points, consistent with patients’ and providers’ perceptions of the endpoint and 
their goals of treatment.  
MATERIALS AND METHODS 
A prospective, questionnaire-based study was designed to assess stakeholder perspectives on 
curative therapy as well as their desired goals of treatment (Supplementary Figure 1). The study 
was performed between November 2016 and May 2017. Participants were approached during the 
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annual pancreatic cancer and related diseases symposium (November 2016, Thomas Jefferson 
University, Philadelphia, PA) and during regular outpatient clinic visits. Surveyed individuals 
included patients, their family members, and clinicians/cancer researchers (i.e, senior surgeons, 
oncologists, clinical researchers, and translational pancreatic cancer researchers). Most patients 
included in the study had previously undergone curative intent pancreatic resection; some had 
already experienced a cancer recurrence. Gender, age and study group (1: Patients, 2: Family 
Members and 3: Clinicians/Clinical pancreatic cancer researchers) were recorded. For 
individuals in group 1 (patients), participants were also asked to indicate whether a 
pancreatectomy was performed.  All participants were asked to review three possible scenarios, 
and select the one which most closely met their definition of a pancreatic cancer cure (See 
Supplementary Figure 1): 
A. Surviving for 5 years (i.e., the literature benchmark). 
B. Having normal laboratory and imaging test results for the rest of your life (i.e., scientific 
definition, an approximation of the NCI statement above). 
C. Living a normal life span, similar to an age-matched person without pancreatic cancer 
(i.e., a practical definition). 
Participants were also asked to rate these statements according to how useful each of the metrics 
were in their view, as compared to the other choices (from the most informative endpoint to the 
least informative). Between-group analysis was then performed using Wilcoxon’s ranked test. 
Within-group determination of internal agreement was performed using R12 (R version 3.3.2, 
2016, The R foundation for statistical computing) with the raters package13 for Fleiss’ Kappa 
test. P values ≤ 0.05 were considered as statistically significant. Questionnaires were indexed by 
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a serial number, and no patient identifiable data were recorded.  The study was approved by the 
Thomas Jefferson University Institutional Review Board.  
RESULTS 
Defining pancreatic cancer cure 
A total of 350 questionnaires were prepared and assigned form identifiers. Of these 200 
questionnaires were returned for analysis (57%). Cohort characteristics and question response 
rates are provided in Tables 1-2. Average question response rates were >95% across each 
subgroup.  Normal life expectancy was the preferred definition for pancreatic cancer cure 
(chosen by 67% of the participants, Figure 1A, P<0.01) in the whole cohort, as well as for each 
questioned sub-group (Figure 1B). Interestingly, while the five year survival endpoint is the 
standard survival endpoint used in the literature, respondents considered this definition to be the 
least meaningful out of the provided choices. Only 5% of respondents preferred this metric. The 
response profile was only slightly different in the researcher/clinician subgroup compared to 
patient and family member subgroups (Figure 1B, P=0.1 and P=0.025, Fisher’s exact test), 
although overall trends were similar.  
The questionnaire’s second question asked for patients to rank the three possible 
definitions based on their subjective informative value. Consistent with the previous question, 
normal life expectancy was selected as the most informative metric (ranked as most important by 
70% of the participants, P<0.01, Figure 2A), as well as in subgroup analyses (Figure 2B-D).  A 
high level of inter-group agreement was found in both the patient and patient family member 
groups (k=0.25 and k=0.40, respectively, P<0.01). In contrast, the internal agreement levels in 
the researcher/clinician subgroup were lower (k=0.09, P<0.01). Thus, the most knowledgeable 




Cure is the desired treatment goal of early, or localized, cancer. This principal is even 
conveyed in our own Sidney Kimmel Cancer Center’s motto: “Until every cancer is cured.”14. It 
therefore seems reasonable to design studies that attempt to capture this important metric, 
particularly since it is acknowledged by patients, family members, and clinicians, during 
discussions of prognosis.  Unfortunately, the biologic definition offered by the NCI (“that there 
are no traces of your cancer after treatment and the cancer will never come back.”) cannot be 
definitively tracked using currently available cancer surveillance technologies.  
Clear, compassionate communication of treatment goals, treatment chances and expected 
survival is a challenge, further complicated but a multitude of different survival metrics and 
conflicting viewpoint and perceptions. In this study, we offer an alternative definition that can 
potentially be quantified and tracked. Moreover, the proposed definition is consistent with the 
endpoints desired by the principal stakeholders, including patients, family members, and health 
care professionals. Individuals completing the study survey considered three possible definitions 
of PDA cure: the standard published outcome metric (5-year survival), a biologic metric similar 
in intent to a scientific definition proposed by the NCI (i.e., any detectable trace of disease), and 
a practical definition (where life span is renormalized).  Each of these definitions has associated 
advantages and disadvantages for use as a metric (Table 3). For instance, the five-year survival 
milestone is frequently used in the surgical oncology literature as a primary outcome measure4 
and is simple to measure. However, the endpoint ignores the fact that late recurrences occur. 
Strikingly, the present study revealed that this oft quoted cancer survival endpoint was the least 
meaningful out of the survey options offered to study participants. The second definition 
considers biologic aspects of cure, and fits best with the NCI definition. However, there is no an 
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available test that can definitively rule out the presence of microscopic and sub-clinical PDA, 
diminishing its practical utility. The definition is purely conceptual. In the real world, PDA 
recurrences are detected using imaging studies and serum tumor markers with sensitivities 
around 90%15-17. Assays that test for circulating tumor cells (CTC) 18 have even lower 
sensitivities (47-68%) 19,20.  Additionally, in other diseases like breast cancer, patients frequently 
harbor sub-clinical bone marrow metastases for decades 21-24 without any impact on quality of 
life or longevity. This finding suggests that a biologic definition would not be practically 
relevant for all patients, especially elderly individuals with other comorbidities. The third 
definition has been under-utilized in the cancer literature, but is recommended by the European 
Conference on Survivors and Chronic Cancer 25.  A determination of ‘normal life expectancy’ 
can be extracted from general population statistical life tables (for example, life tables from the 
Social Security Administration). In fact, all stakeholders in the present study highlighted 
renormalization of life expectancy as the preferred definition of PDA cure. From a practical 
standpoint, a patient living a normal life span would be considered to be cured by most 
stakeholders, even if a test were able to detect subclinical and microscopic disease. While 
biologically speaking, the patient in this case would not have been considered as cured, in terms 
of cancer treatment goals, most stakeholders in our study preferred that endpoint to the 
standardly used endpoint of 5 years of cancer free survivorship. 
The manner in which prognosis is conveyed to patients and family members can have 
major emotional and social consequences. For instance, the term ”cancer survivorship” is a 
stressful reminder for some patients that a threat of recurrence looms26. For others, ‘survivorship’ 
offers a sense of personal growth and achievement. Terms such as ‘cured’, ‘healed’, and 
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remission are more optimistic25, but their intended meaning can be misinterpreted. Indeed, this 
study reveals the range of possible interpretations of “cure” in the context of pancreatic cancer.  
For PDA, the actual cure rate has never been effectively quantified. Even “early” PDA 
lesions (< 2 cm invasive component) have a tendency to spread and recur more frequently than 
other similarly sized cancer types 27.  Long-term survival studies reveal that patients with 
resected PDA reach the 5-year time point roughly 20% of the time 6,28-30; thus, actual cure rates 
must be lower than this number. Studies with longer follow-up intervals report that PDA 
recurrences occur more than 10 years after resection 6. In fact, conditional survival analyses 
show that patients who survive five years after resection still have an excess mortality rate 
compared to the general population 31.  
Limiting and biasing factors 
Several biasing factors in our study limit the interpretation and generalization of the 
results. First, this is a single center study. In addition, the vast majority of patient participants 
underwent a pancreatic resection (>92%). Most of the patient participants had relatively early 
and surgically managed pancreatic tumors at presentation. Therefore, perspectives of patients 
who presented with advanced or metastatic disease are not well represented in this survey. While 
we have tried to minimize misinformation bias by verbally explaining each of the proposed 
definitions during the survey, it is possible that some of the patients misunderstood the questions 
or believed some definitions to be inclusive of the other ones.  The cross-sectional design of our 
study at a single time point also does not consider individual shifts in perspective or opinion over 
time. Also, we do not evaluate perceptions of cure for other tumor types.  Finally, none of these 
definitions precisely and accurately describe the scientific definition of cure. Rather, they 




Patient-Clinician communication regarding pancreatic cancer cure is complex and prone 
to misperception regarding the informative value of different survival statistics. A normal life 
expectancy was the most important long-term outcome metric according to patients with early-
staged pancreatic cancer.  Clinicians should be mindful in discussion of prognosis that actual 
PDA cure rates have not been rigorously determined and remain unknown. Further, the meaning 
of cure may not be fully understood by patients and family members.  Importantly, the preferred 
definition identified in this study - renormalization of anticipated life expectancy – is actually 
estimable. This outcome can be calculated through comparisons of PDA survival data and data 
from actuarial life tables of age-matched individuals in the general population. Based on these 
results, we submit that this new outcome metric (i.e., renormalization of life expectancy) should 
be determined for PDA patients, and serve as a new benchmark for scientific progress, with the 
ultimate research goal to improve cure rates. Ongoing work in this area by our group is intended 
to meet this objective. 
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%Male % Curative-intent 
Pancreatic Resection 
Patients (N=93) 65.5 ± 1.2 61% 92.3% 
Family members (N=53) 55.4 ± 2.3 27%  
Researchers/Clinicians (N=52) 36.8 ± 1.5 33% 
Other (N=2) 27 0% 
 







Best Cure Definition 
Item#2* 
Perceived Informative Value 
Patients (N=93) 93 (100%) 87 (94%) 
Family members (N=53) 49 (92%) 52 (98%) 
Researchers/Clinicians (N=52) 52 (100%) 52 (100%) 
Other (N=2) 1 (50%) 1 (50%) 
Missing Data 5  8  
Total 200 200 
 
Table 2. Questionnaire item completion rates (in parenthesis, relative item completion rates in 










Surviving for 5 
years. 
• Easy to measure and interpret in 
clinical studies 
• Easy to compare across various 
groups and cancers.  
• Requires a defined short follow 
up period   
• Uninformative for pathologies 
with high survival rate 
• Generalized and not patient 
specific 
• Does not capture dormant 





imaging test results 
for the rest of your 
life. 
• Easy to comprehend by non-
health professionals. 
• Closest measurable scientific 
endpoint for ‘cure’  
• Requires very long term follow-
up 
• Over-interprets dormant and 
clinically irrelevant  disease 
• Does not necessarily correlate 
with survival 
• Difficult to compare across 




Living a normal life 
expectancy, similar 
to a person without 
pancreatic cancer 
• Patient specific 
• Easy to comprehend by non-
health professionals. 
• Requires a defined follow up 
period (varies between patients).   
• Allows for existence of active or 
dormant disease 
• Complicate clinical study design 
(requires individual age-adjusted 
follow-up durations for patients)  
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• Easy to compare across various 
groups and cancers.  
 






Figure 1. (A) Participants’ answer distribution for definition of endpoint of cure of pancreatic 
cancer (P<0.01, χ2 test). (B) Sub-population comparison of participants’ answer distribution for 
definition of endpoint of cure of pancreatic cancer (χ2 test). 
Figure 2. Overall and Sub-population comparison of participants’ ranking of three proposed 
long-term endpoint metrics for their informative value in pancreatic cancer (Fleiss’ kappa 
analysis).  
Supplementary Figure 1. Participant Questionnaire 
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